Maternal Chemical and Drug Intolerances: Potential Risk Factors for Autism and Attention Deficit Hyperactivity Disorder (ADHD)
==============================================================================================================================

* Lynne P. Heilbrun
* Raymond F. Palmer
* Carlos R. Jaen
* Melissa D. Svoboda
* Jimmy Perkins
* Claudia S. Miller

## Abstract

*Purpose:* The aim of this study was to assess whether chemically intolerant women are at greater risk for having a child with autism spectrum disorders (ASD) or attention deficit hyperactivity disorder (ADHD).

*Methods:* We conducted a case–control study of chemical intolerance among mothers of children with ASD (n = 282) or ADHD (n = 258) and children without these disorders (n = 154). Mothers participated in an online survey consisting of a validated chemical intolerance screening instrument, the Quick Environmental Exposure and Sensitivity Inventory (QEESI). Cases and controls were characterized by parental report of a professional diagnosis. We used a one-way, unbalanced analysis of variance to compare means across the 3 groups.

*Results:* Both mothers of children with ASD or ADHD had significantly higher mean chemical intolerance scores than did mothers of controls, and they were more likely to report adverse reactions to drugs. Chemically intolerant mothers were 3 times more likely (odds ratio, 3.01; 95% confidence interval, 1.50–6.02) to report having a child with autism or 2.3 times more likely (odds ratio, 2.3; 95% confidence interval, 1.12–5.04) to report a child with ADHD. Relative to controls, these mothers report their children are more prone to allergies (*P* < .02), have strong food preferences or cravings (*P* < .003), and have greater sensitivity to noxious odors (*P* < .04).

*Conclusion:* These findings suggest a potential association between maternal chemical intolerance and a diagnosis of ADHD or ASD in their offspring.

*   Attention Deficit Hyperactivity Disorder
*   Autism Spectrum Disorder
*   Chemical Exposure
*   Chemical Intolerance
*   Maternal Exposure

Developmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), now affect 1 in 6 children in the United States,1 a trend that is changing the spectrum of patients who visit family physicians. According to the Centers for Disease Control and Prevention, ASDs now affect 2% of US children,2 an 8-fold increase since the early 1990s.3 ADHD affects 9.5% of children ages 4 to 17 years, up 5.5% per year for the period between 2003 to 2007.4 Proposed reasons for the recent increase in ASD cases include greater awareness, changes in diagnostic criteria, and younger ages at diagnosis. However, these factors seem to account for only one third of the increase in ASD since the early 1990s.3

How are these prevalence changes affecting primary care practice? First, compared with children with asthma, children with ADHD are 3.5 times more likely to have an unmet medical need.5 Children with ASD often suffer from comorbid asthma, allergies, recurrent ear infections, immune system dysfunction, and gastrointestinal disorders, further increasing the demand on primary care practices.6,7 Primary care physicians are often first to recognize ASD or ADHD and are uniquely positioned to coordinate care for these families,8 but they feel less able to treat children with ASD compared with typically developing children, citing a lack of knowledge of available resources and insufficient training.9

## Environmental Exposures Can Adversely Affect Neurodevelopment

Gene–environment interactions underlie both ASD and ADHD. Recent twin studies estimate that genes account for about 38% of the heritability of autism, whereas environmental factors account for 58%.10 Children are especially vulnerable to adverse effects from toxic exposures. Numerous studies of humans demonstrate an association between chemical exposures and impaired neurodevelopment.11⇓–13 Prenatal exposure to organophosphorus pesticides is a risk factor for the development of ASD14 and ADHD,15 and is known to impair neurodevelopment in children.16 Proximity to vehicle traffic and coal-fired power plants also are recognized risk factors for both ADHD and ASD.17⇓–19 Since World War II, the types and levels of volatile organic chemicals inside homes and offices, where people in developed countries spend 90% of their day, have increased dramatically.20 Among the chemical exposures implicated in ASD are styrene, vinyl flooring, methylene chloride, elemental mercury, and antibacterial quinolone.21,22

A number of medications used during pregnancy increase the risk of ASD and ADHD.23,24 Strong evidence supports a causal relationship between ASD and in utero exposure to the medications valproic acid, thalidomide, and misoprostol.25⇓⇓⇓–29 For example, thalidomide taken early in pregnancy is associated with autism and, if taken later, may result in the characteristic limb deformities (phocomelia).

### Chemical Intolerance

Chemical intolerance (CI) affects an estimated 10% to 30% of the US population and occurs worldwide across a range of demographic groups and ages.30⇓⇓⇓⇓–35 These individuals typically report adverse effects from low-level exposure to a wide variety of chemicals, as well as to foods, drugs, caffeine, and alcohol. These intolerances manifest as multisystem symptoms that frequently involve the central nervous system and often develop following a well-defined exposure event, such as home remodeling or extermination. This disease process has been called “toxicant-induced loss of tolerance.” Some affected individuals may not recall a particular initiating exposure.36 In a recent study of primary care clinic patients, 20% met the criteria for chemical intolerance but only one quarter of these individuals had been diagnosed with the condition.35 Researchers from this study assert that intolerances to chemicals and/or foods are potential underlying causes for illness that are rarely identified by busy practitioners but instead must be actively sought. The underlying pathophysiology of CI/toxicant-induced loss of tolerance seems to involve genetic susceptibility as well as exposure. No studies have examined developmental outcomes of children born to women who report CI. The purpose of this study was to explore whether a mother's CI might be related to her risk of having a child diagnosed with ASD or ADHD.

## Methods

### Study Design: Assessing CI

The most widely used instrument for evaluating CI in adult populations is the Quick Environmental Exposure and Sensitivity Inventory (QEESI), which is both sensitive (92%) and specific (95%) for CI.37,38 Researchers from various countries, including the United States, Japan, and Germany, have used the QEESI to assess CI.39⇓–41

The QEESI consists of five self-rating scales, with 10 questions each. The four core intolerance scales include Chemical Exposures, Other Exposures, Symptoms, and Impact of Sensitivities. Each scale contains 10 items that are to be rated 0 to 10 in terms of the severity of symptoms. A fifth scale, the Masking Index, provides a measure of an individual's ongoing exposures. The two scales most indicative of CI and used for this study are Chemical Exposures and Symptoms.37,38 Refer to the Appendix for an assessment of subjects' intolerances and symptoms.

In this case–control study mothers responded to a secure computer-based survey that included the QEESI and questions on demographics and exposure/medical histories. The survey was available on the website of Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD), a nationally recognized ADHD organization, and was advertised through community agencies and groups involved with ASD treatment and early childhood development (eg, Easter Seals). The study was reviewed and approved by the institutional review board at the University of Texas Health Science Center at San Antonio.

Case participants were biological mothers, 18 years of age or older, reporting at least 1 child with a professional diagnosis of ASD or ADHD. Other studies have shown that parents who participate in online recruitment accurately report a diagnosis of ASD in their children.42,43 Further, Daniels et al.43 demonstrated a 98% concordance between parent-reported and professionally diagnosed ASD, supporting the utility of online recruitment. To confirm an ADHD diagnosis in their children, mothers responded to criteria derived from the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision (DSM-IV-TR).44

Case participants were asked to help recruit controls from among friends or colleagues whose children had no professionally diagnosed neurological, behavioral, or developmental disorders. Mothers of cases were asked to share the study/contact information through E-mail or word of mouth to these friends/colleagues. These potential control recruits were directed to the website by the project coordinator. Case and control responses to the *Diagnostic and Statistical Manual of Mental Disorders* criteria for ADHD were evaluated to ensure consistency with self-report.

### Hypothesis and Statistical Analysis

We hypothesized that mothers with higher CI scores, as measured by the QEESI, would be more likely to report having children with ASD or ADHD. Our secondary hypothesis was that mothers of children with ASD or ADHD, compared with control mothers, would report more adverse medical events and environmental intolerances in their children.

Statistical differences in average QEESI scores between cases and controls were tested using a one-way, unbalanced analysis of variance to compare means across the three groups. The Dunnett test was used to address multiple pairwise comparisons that may contribute to the type I error rate.45 χ2 tests were used to determine whether there were significant differences in dichotomous characteristics between cases and controls. A logistic model was used to predict the presence or absence of adverse medical events and environmental intolerances between the children serving as cases and controls. The models were adjusted for the number of comorbid conditions and mother's marital status. All tests were conducted at the α = 0.05 level of significance using SAS software (SAS Institute, Inc., Cary, NC).

## Results

Table 1 shows demographic distributions across the three groups (ASD, n = 282; ADHD, n = 258; controls, n = 154). We screened the first 135 respondents for ADHD case/control accuracy using the mothers' responses to the DSM-IV-TR criteria. We found 3.7% in error; that is, they reported that their child did not have a professional diagnosis, but the child met the DSM-IV-TR criteria, or vice versa. We chose not to screen additional respondents because of the small error rate. Mother's age, education, and ethnicity; family income; and the number of children did not differ significantly across groups. Of the mothers of children with ADHD, approximately 20% fewer were married compared with mothers of children with ASD or controls (*P* < .01). Mothers of children with ADHD reported significantly more comorbid conditions than mothers of children with ASD or controls. Based on these differences, subsequent analysis was adjusted for marital status and comorbid conditions.

View this table:
[Table 1.](http://www.jabfm.org/content/28/4/461/T1)

Table 1. Descriptive Statistics Among Mothers of Children With Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder and Control Children

Group comparisons of the QEESI's CI total and item scores are shown in Table 2. Both mothers of children with ASD and mothers of children with ADHD had significantly higher mean CI scores than did mothers of control. Mothers of children with ASD and ADHD, compared with mothers of control, were more intolerant of insecticides, gasoline, engine exhaust, paint or paint thinner, nail polish or hairspray, and outgassing from new materials such as carpet, shower curtains, or new car interiors. In addition, compared with mothers of controls, mothers of children with ADHD were more intolerant of tobacco smoke and perfume. Mothers of children with ASD were more sensitive to tar/asphalt.

View this table:
[Table 2.](http://www.jabfm.org/content/28/4/461/T2)

Table 2. Comparison of Chemical Intolerance (Quick Environmental Exposure and Sensitivity Inventory) Scores Among the Mothers of the 3 Groups of Children

For the total Symptoms scale score (Table 3), mothers of children with ADHD or ASD differed significantly from mothers of controls in their difficulty with thinking, concentrating, memory, and mood. In addition, these mothers differed significantly from mothers of controls in problems with muscle and joint pain, aching, cramping, and stiffness, as well as problems with burning eyes, airway, breathing, and coughing.

View this table:
[Table 3.](http://www.jabfm.org/content/28/4/461/T3)

Table 3. Average Quick Environmental Exposure and Sensitivity Inventory Symptoms Scores for Mothers of Cases and Controls

Scores ≥40 on both the Symptoms scale and Chemical Exposure scale are highly suggestive of CI.37,38 Importantly, mothers with scores ≥40 on both the Symptoms and Chemical Exposure scales were three times more likely to report having a child with ASD (odds ratio [OR], 3.01; 95% confidence interval [CI], 1.50–6.02). Similarly, for ADHD, mothers whose scores were ≥40 on both the Symptoms and Chemical Exposure scales were 2.3 times more likely to report having a child with ADHD (OR, 2.3; 95% CI, 1.12–5.04). To determine whether the Symptoms scale was potentially driven by two behavioral items commonly found in families with ADHD (problems with ability to think, difficulty concentrating, remembering; problems with mood, tense or nervous, depressed), these items were removed from the scale and the responses were reanalyzed. The results were the same and did not change the interpretation presented above.

Notably, the significant distinguishing items between mothers of cases (both ASD and ADHD) and controls on the Other Exposures scale was the inability to tolerate certain drugs or having had adverse drug reactions (*P* < .01) and problems with classic allergic reactions when exposed to allergens (*P* < .05; data not shown).

In Table 4, children's medical and intolerance outcomes are predicted by their ASD or ADHD status. Compared with control children, children with ASD or ADHD were, according to their mothers, significantly more likely to have sensitivities to odors, problems with allergies, and strong food preferences or cravings. Compared with mothers of controls, mothers of children with ASD were statistically more likely to report that their children had food or other allergies/intolerances; an adverse reaction to a vaccination, prompting a call to the doctor; ear infections requiring tube placement; and multiple infections requiring prolonged use of antibiotics.

View this table:
[Table 4.](http://www.jabfm.org/content/28/4/461/T4)

Table 4. Mother's Report of Their Children's Illnesses or Responses to Common Exposures

## Discussion

Our results suggest that mothers with CI are more likely to have children with ASD or ADHD than mothers without CI. Compared with controls, mothers with CI from our study report more cognitive and affective symptoms, consistent with the broader literature showing increased cognitive and mood disorders among families with children with ASD and ADHD.46,47

Notably, compared with mothers of controls, mothers of children with ASD or ADHD were significantly more likely to report that their children were especially sensitive to a wide range of chemical odors—the hallmark symptom of CI. These mothers also were significantly more likely to report that their children have problems with allergies, sensitivities, infections, reactions to drugs (oral or injected), and/or foods than mothers of neurotypical children. The recent literature supports comorbid allergies and food cravings/sensitivities in both children with ASD and children with ADHD.48⇓–50 Neurodevelopmental comorbidities in children with ASD and children with ADHD are the norm rather than the exception; therefore, eliminating children on this basis would not be feasible. Medical comorbidities also are common among children with these disorders. In our sample, for both ASD and ADHD these comorbidities included mental retardation, anxiety, epilepsy, auditory and visual processing disorders, depression, and obsessive compulsive disorders.

Our findings are consistent with our hypothesis that mothers with CI are more apt to have children with similar intolerances. Children who inherit their mothers' susceptibilities may be at greater risk from exposure to toxicants, either in utero or after birth.

We tested mothers' current CI, which does not tell us whether she had it before pregnancy; it simply tells us that she may be more vulnerable to toxins. Although this study is neither a genetic study nor a prospective chemical exposure study, our data may suggest that children inherit these susceptibilities and intolerances. Increased nitrite/nitrate and inflammatory cytokine levels as well as genetic polymorphisms in detoxification enzymes have recently been implicated in CI.51 One well-understood example of mothers conferring susceptibility to environmental chemicals involves pesticide exposure. Mothers who are less able to detoxify organophosphorus pesticides because of low paraoxonase enzyme activity are at increased risk for having children with ASD and ADHD.52,53 Studies by Singh et al54,55 provide evidence that individuals with more susceptible genotypes who are exposed to organophosphorus pesticides exhibit greater DNA damage. Thus, “dose plus host” determines toxicity.

Primary care physicians may be first in line to recognize and refer a child with symptoms of ADHD or ASD. Thus, it is important for them to develop practical plans for screening and referral. Because of the many comorbid health conditions associated with ASD and ADHD, these children and their families have many unmet medical needs.5,7,9 The availability of a medical home for family care may reduce these burdens.7 Future medical homes need to address the family's *actual* home environment. For doctors in already overburdened practices, taking time to obtain an exposure history and discuss environmental interventions may seem overwhelming. Primary care physicians could, however, offer Table 5 as a preconception precautionary tool, since roughly one third of pregnant women reported seeing a primary care physician within the previous year.56

View this table:
[Table 5.](http://www.jabfm.org/content/28/4/461/T5)

Table 5. Recommendations for Reducing Exposures

In the recent past, doctors were hesitant to advise women to avoid alcohol and tobacco during pregnancy for fear of making the mothers feel guilty or worried about their pregnancy, even though there was sufficient evidence to do so. The American College of Obstetricians and Gynecologists recently issued a position statement recommending timely action to reduce additional exposures: “The evidence that links exposure to toxic environmental agents and adverse reproductive and developmental health outcomes is sufficiently robust….”57 Home environmental interventions to help children with ASD or ADHD could have the dual benefit of reducing exposures that may be affecting the health of other family members. Asthma and migraines can be exacerbated by tobacco smoke, pesticides, new construction/remodeling, and fragrances. Recommendations in Table 5 may reduce symptoms of asthma and other environmentally related illnesses and can encourage families to share responsibility for their own health.

Families are most receptive to making major lifestyle changes, such as reducing smoking and chemical use, when they are expecting a new arrival. This is consistent with the applications of the precautionary principle in public health, which indicates that if there is potential threat of harm to human or environmental health, precautionary measures should be taken to avoid the threat even before there is scientific consensus concerning cause and effect. This implies that there is a social responsibility to protect the public from harm when a plausible risk is present.

### Limitations

These data are cross-sectional, and causal mechanisms cannot be inferred because of confounders in this limited sample. Ours was a large, self-selected convenience sample (n = 694) mainly consisting of non-Hispanic white, educated women responding to an online survey. Our sample demographics are consistent with those of other online studies.58 While the “digital divide” between affluent and nonaffluent people is slowly closing over time,59 we cannot verify a representative sample, and therefore these results must be generalized to other populations with caution. Self-selection is based on a willingness to participate, and mothers with an affected child would be more willing than those with an unaffected child, adding potential sampling biases. Mothers of children with ASD or ADHD may be more attuned to searching for causes for their child's condition,60 potentially resulting in overreporting of exposures compared with controls. Fewer friend/colleague controls were recruited than cases. Further, the lower response rate from control mothers may be the result of less interest in the study outcome because their children are neurotypical and they are not intrinsically motivated to learn about what may contribute to autism or ADHD. Therefore, this study may not be considered a rigorous case–control study because the recruitment of cases and controls have inherent biases affecting generalizability.61 The extent to which these biases affect our results is unknown; therefore, more rigorous epidemiologic studies are needed to verify the results of this study.

## Conclusion

These data provide preliminary evidence for an association between maternal CI and risk of ASD and ADHD in children. Further studies are needed to confirm these findings. We are dealing with a public health emergency with the increase in neurodevelopmental disorders, however, and it is incumbent on us to take appropriate preventive steps. Establishing clear cause-and-effect relationships between neurodevelopmental disorders and exposures may require decades of costly epidemiologic studies. In the meantime, primary care physicians should advocate a precautionary approach, as recommended by the American College of Obstetricians and Gynecologists, to encourage women of childbearing age to avoid unnecessary exposures.57

## Appendix

#### The Quick Environmental Exposure and Sensitivity Inventory

The QEESI is a validated instrument to assess CI in adults.37,38 The QEESI consists of self-rating scales for symptoms, as well as responses to chemical and other common exposures, including foods, skin contactants, alcoholic beverages, and caffeine. Each of these three scales (Symptoms, Chemical Exposures, and Other Exposures) contains 10 items that participants rate from 0 to 10 in terms of the severity of their responses. The development, validation, sensitivity, and specificity of these scales are published elsewhere.37,38,62

##### Symptoms Scale

The Symptoms scale includes head-related, musculoskeletal, respiratory/mucus membrane, heart/chest, neuromuscular, gastrointestinal, cognitive, affective, skin, and genitourinary symptoms. Scoring for this scale is accomplished by asking participants to rate each item from 0 to 10 in a manner that best corresponds with the severity of their symptoms and responses to various substances: 0 = not a problem, 5 = moderate, 10 = severe or disabling. Scores on the 10 items for each scale are tallied to obtain a total scale score (0–100).

##### Chemical Exposures Scale

This scale asks participants about the severity of their responses to 10 common structurally diverse inhalants, rated from 0 to 10, as described above. Items include diesel or gas engine exhaust, tobacco smoke, insecticide, gasoline vapors, paint/paint thinner, fragrances, cleaning products, fresh tar or asphalt, nail polish/nail polish remover, hairspray, and new furnishings.

##### Other Exposures Scale

The Other Exposures scale includes 10 additional questions concerning the severity of the subjects' responses to a variety of other common exposures (noninhalants), again asking them to rate their response severity from 0 to 10. These items include chlorinated tap water, foods/food additives, unusual cravings or feeling ill if a meal is missed, feeling ill after meals, caffeine, caffeine withdrawal, small amounts of alcoholic beverages, skin contactants, medical drugs/devices, and allergens (causing classic allergic responses of asthma, nasal symptoms, hives, eczema, or anaphylaxis).

#### Mother's Report of Children's Illnesses and Reponses to Exposures

Each mother was asked about her child's sensitivities and responses to various common exposures. Included were questions concerning (1) reactions to vaccinations that prompted a call to the doctor; (2) ear infections requiring tubes placed in the ears; (3) multiple infections requiring prolonged use of antibiotics; (4) sensitivity to odors such as smoke, nail polish remover, exhaust, gasoline, air fresheners, or cleaning supplies (by sensitive, we mean does this child become nauseated, get headaches, have trouble breathing, feel dizzy, or try to move away from the odor); (5) food allergies or intolerances; (6) strong food preferences/cravings such as cheese, chips, bread, pasta, rice, sugar, salt, chocolate; (7) illness following an environmental exposure; (8) allergies; and (9) asthma. See [http://drclaudiamiller.com/qeesitest/](http://drclaudiamiller.com/qeesitest/) for printable copy for use in your practice.

## Notes

*   This article was externally peer reviewed.

*   *Funding:* The research described in this paper has been funded wholly or in part by the United States Environmental Protection Agency (EPA) under the Science to Achieve Results (STAR) Graduate Fellowship Program. We would to acknowledge the Department Family and Community Medicine Department at UTHSCSA for its support and resources for this project.

*   *Conflict of interest:* none declared.

*   Received for publication July 4, 2014.
*   Revision received February 2, 2015.
*   Accepted for publication February 4, 2015.

## References

1.  1.Boyle CA, Boulet SL, Schieve LA, et al. Trends in the prevalence of developmental disabilities in U.S. children, 1997–2008. Pediatrics 2011;127:1034–42.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6MTA6IjEyNy82LzEwMzQiO3M6NDoiYXRvbSI7czoyMDoiL2phYmZwLzI4LzQvNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

2.  2.Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011–2012. Natl Health Stat Report 2013;(65):1–11, 1 p following 11.
    
    

3.  3.Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009;20:84–90.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1097/EDE.0b013e3181902d15&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=19234401&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000261930800016&link_type=ISI) 

4.  4.Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children**—**United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439–43.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21063274&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

5.  5.Toomey SL, Finkelstein J, Kuhlthau K. Does connection to primary care matter for children with attention-deficit/hyperactivity disorder? Pediatrics 2008;122:368–74.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6OToiMTIyLzIvMzY4IjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

6.  6.Brachlow AE, Ness KK, McPheeters ML, Gurney JG. Comparison of indicators for a primary care medical home between children with autism or asthma and other special health care needs: National Survey of Children's Health. Arch Pediatr Adolesc Med 2007;161(4):399–405.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1001/archpedi.161.4.399&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=17404138&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

7.  7.Kogan MD, Strickland BB, Blumberg SJ, Singh GK, Perrin JM, van Dyck PC. A national profile of the health care experiences and family impact of autism spectrum disorder among children in the United States, 2005–2006. Pediatrics 2008;122:e1149–58.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6MTE6IjEyMi82L2UxMTQ5IjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

8.  8.Leslie L. The role of primary care physicians in attention deficit hyperactivity disorder (ADHD). Pediatr Ann 2002;31:475–84.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=12174762&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000177375500005&link_type=ISI) 

9.  9.Golnick AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord 2009;39:996–1005.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1007/s10803-009-0714-7&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=19280328&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

10. 10.Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011;68:1095–102.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1001/archgenpsychiatry.2011.76&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21727249&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000296649800004&link_type=ISI) 

11. 11.Wigle DT, Arbuckle TE, Walker M, Wade MG, Liu S, Krewski D. Environmental hazards: evidence for effects on child health. J Toxicol Environ Health B Crit Rev 2007;10:3–39.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18074303&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000243429300002&link_type=ISI) 

12. 12.Pessah I, Seegal RF, Lein PJ, et al. Immunologic and neurodevelopmental susceptibilities of autism. Neurotoxicology 2008;29:532–45.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.neuro.2008.02.006&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18394707&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

13. 13.Hertz-Picciotto I, Park HY, Dostal M, Kocan A, Trnovec T, Sram R. Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development. Basic Clin Pharmacol Toxicol 2008;102:146–54.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18226068&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000252588900013&link_type=ISI) 

14. 14.Rauh VA, Garfinkel R, Perera FP, et al. Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics 2006;118:1845–59.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1542/peds.2006-0338&link_type=DOI) 

15. 15.Bouchard MF, Bellinger DC, Wright RO, Weisskopf MG. Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides. Pediatrics 2010;125(6):e1270–7.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6MTE6IjEyNS82L2UxMjcwIjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

16. 16.Rosas LG, Eskenazi B. Pesticides and child neurodevelopment. Curr Opin Pediatr 2008;20:191–7.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1097/MOP.0b013e3282f60a7d&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18332717&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000254792900015&link_type=ISI) 

17. 17.Siddique S, Banerjee M, Ray MR, Lahiri T. Attention-deficit hyperactivity disorder in children chronically exposed to high level of vehicular pollution. Eur J Pediatr 2011;170:923–9.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1007/s00431-010-1379-0&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21191614&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

18. 18.Volk HE, Lurmann F, Penfold B, Hertz-Picciotto I, McConnell R. Traffic-related air pollution, particulate matter, and autism. JAMA Psychiatry 2013;70:71–7.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=23404082&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

19. 19.Palmer RF, Blanchard S, Wood R. Proximity to point sources of environmental mercury release as a predictor of autism prevalence. Health Place 2009;15:18–24.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.healthplace.2008.02.001&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18353703&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000261636300003&link_type=ISI) 

20. 20.Weschler CJ. Changes in indoor pollutants since the 1950s. Atmos Environ 2009;43:153–69.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.atmosenv.2008.09.044&link_type=DOI) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000262147400016&link_type=ISI) 

21. 21.Sundell J. Indoor environments and health. Presented at the First International Conference on Sustainable Healthy Buildings, Seoul, Korea, 2009.
    
    

22. 22.Kalkbrenner AE, Daniels JL, Chen JC, Poole C, Emch M, Morrissey J. Perinatal exposure to hazardous air pollutants and autism spectrum disorders at age 8. Epidemiology 2010;21:631–41.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1097/EDE.0b013e3181e65d76&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=20562626&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000281021100015&link_type=ISI) 

23. 23.Croen L, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104–12.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1001/archgenpsychiatry.2011.73&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21727247&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000296649800005&link_type=ISI) 

24. 24.Figueroa R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr 2010;31:641–8.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1097/DBP.0b013e3181e5ac93&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=20613624&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

25. 25.Strömland V, Nordin M, Miller B, Akerström B, Gillberg C. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 1994;36:351–6.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=8157157&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1994NB34700010&link_type=ISI) 

26. 26.Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J Dev Neurosci 2005;23:189–99.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.ijdevneu.2004.11.001&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=15749245&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000227943900007&link_type=ISI) 

27. 27.Bandim JM, Ventura LO, Miller MT, Almeida HC, Costa AE. Autism and Möbius sequence: an exploratory study of children in northeastern Brazil. Arq Neuropsiquiatr. 2003.
    
    

28. 28.Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489–97.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiam1lZGdlbmV0IjtzOjU6InJlc2lkIjtzOjg6IjM3LzcvNDg5IjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

29. 29.Rodier PM. Converging evidence for brain stem injury in autism. Dev Psychopathol 2002;14:537–57.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1017/S0954579402003085&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=12349873&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000178214600008&link_type=ISI) 

30. 30.Kruetzer R, Neutra R, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol 1999;150:1–12.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYW1qZXBpZCI7czo1OiJyZXNpZCI7czo3OiIxNTAvMS8xIjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

31. 31.Bell IR, Schwartz GE, Peterson JM, Amend D. Self-reported illness from chemical odors in young adults without clinical syndromes or occupational exposures. Arch Environ Health 1993;48:6–13.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1080/00039896.1993.9938387&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=7680851&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1993KU12400002&link_type=ISI) 

32. 32.Bell IR, Hardin EE, Baldwin CM, Schwartz GE. Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities. Environ Res 1995;70:84–97.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=8674484&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1995UW19100002&link_type=ISI) 

33. 33.Bell IR, Peterson JM, Schwartz GE. Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. J Clin Psychiatry 1995;56:151–60.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=7713854&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1995QU07800005&link_type=ISI) 

34. 34.Caress SM, Steinemann AC. A national population study of the prevalence of multiple chemical sensitivity. Arch Intern Med 2004;59:300–5.
    
    

35. 35.Katerndahl DA, Bell IR, Palmer RF, Miller GS. Chemical intolerance in primary care settings: prevalence, comorbidity, and outcomes. Ann Fam Med 2012;10:357–65.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiYW5uYWxzZm0iO3M6NToicmVzaWQiO3M6ODoiMTAvNC8zNTciO3M6NDoiYXRvbSI7czoyMDoiL2phYmZwLzI4LzQvNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

36. 36.Miller CS. Toxicant-induced loss of tolerance. Addiction 2001;96:115–37.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1046/j.1360-0443.2001.9611159.x&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=11177524&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000166521700009&link_type=ISI) 

37. 37.Miller CS, Prihoda TJ. A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity. Toxicol Ind Health 1999;15:386–97.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToic3B0aWgiO3M6NToicmVzaWQiO3M6MTA6IjE1LzMtNC8zODYiO3M6NDoiYXRvbSI7czoyMDoiL2phYmZwLzI4LzQvNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

38. 38.Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health 1999;15:370–85.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToic3B0aWgiO3M6NToicmVzaWQiO3M6MTA6IjE1LzMtNC8zNzAiO3M6NDoiYXRvbSI7czoyMDoiL2phYmZwLzI4LzQvNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

39. 39.Hojo S, Kumano H, Yoshino H, Kakuta K, Ishikawa S. Application of Quick Environment Exposure Sensitivity Inventory (QEESI) for Japanese population: study of reliability and validity of the questionnaire. Toxicol Ind Health 2003;19:41–9.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToic3B0aWgiO3M6NToicmVzaWQiO3M6OToiMTkvMi02LzQxIjtzOjQ6ImF0b20iO3M6MjA6Ii9qYWJmcC8yOC80LzQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

40. 40.Schnakenberg E, Fabig KR, Stanulla M, et al. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environ Health 2007;6:6.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1186/1476-069X-6-6&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=17291352&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

41. 41.Skovbjerg S, Berg ND, Elberling J, Christensen KB. Evaluation of the Quick Environmental Exposure and Sensitivity Inventory in a Danish population. J Environ Public Health 2012;2012:304314.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=22529872&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

42. 42.Lee H, Marvin AR, Watson T, et al. Accuracy of phenotyping of autistic children based on internet implemented parent report. Am J Med Genet B Neuropsychatr Genet 2010;153B:1119–26.
    
    

43. 43.Daniels AM, Rosenberg RE, Anderson C, Law JK, Marvin AR, Law PA. Verification of parent-report of child autism spectrum disorder diagnosis to a web-based autism registry. J Autism Dev Disord 2012;42:257–65.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1007/s10803-011-1236-7&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21468770&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

44. 44.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text rev. Washington, DC: APA; 2000.
    
    

45. 45.Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y. Multiple comparisons and multiple tests using the SAS system. Cary, NC: SAS Institute; 1999.
    
    

46. 46.Lajiness-O'Neill R, Menard P. Brief report: an autistic spectrum subtype revealed through familial psychopathology coupled with cognition in ASD. J Autism Dev Disord 2008;38:982–7.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=18034295&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

47. 47.Schachar RJ, Wachsmuth R. Hyperactivity and parental psychopathology. J Child Psychol Psychiatry 1990;31:381–92.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1111/j.1469-7610.1990.tb01576.x&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=2318920&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1990DJ26000004&link_type=ISI) 

48. 48.Davis C, Curtis C, Levitan RD, Carter JC, Kaplan AS, Kennedy JL. Evidence that “food addiction” is a valid phenotype of obesity. Appetite 2011;57:711–7.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.appet.2011.08.017&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21907742&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

49. 49.Gruss B, Mueller A, Horbach T, Martin A, de Zwaan M. Attention-deficit/hyperactivity disorder in a prebariatric surgery sample. Eur Eat Disord Rev 2012;20:e103–7.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21796736&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

50. 50.Macfabe D. Autism: metabolism, mitochondria, and the microbiome. Glob Adv Health Med 2013;2:52–66.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.7453/gahmj.2013.089&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=24416709&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

51. 51.De Luca C, Gugliandolo A, Calabrò C, Currò M, Ientile R, Raskovic D, et al. Role of polymorphisms of inducible nitric oxide synthase and endothelial nitric oxide synthase in idiopathic environmental intolerances. Mediators Inflamm. 2015; Epub 2015 Mar 24.
    
    

52. 52.Gaita L, Manzi B, Sacco R, et al. Decreased serum arylesterase activity in autism spectrum disorders. Psychiatry Res 2010;180:105–13.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.psychres.2010.04.010&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=20488557&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

53. 53.Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 2006;16:183–90.
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=16495777&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=000246126900004&link_type=ISI) 

54. 54.Singh S, Kumar V, Thakur S, et al. DNA damage and cholinesterase activity in occupational workers exposed to pesticides. Environ Toxicol Pharmacol 2011;31:278–85.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.etap.2010.11.005&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21787695&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

55. 55.Singh S, Kumar V, Thakur S, et al. Paraoxonase-1 genetic polymorphisms and susceptibility to DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol Appl Pharmacol 2011;252:130–7.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1016/j.taap.2011.01.014&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=21291901&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 

56. 56.Kozhimannil KB, Fontaine P. Care from family physicians reported by pregnant women in the United States. Ann Fam Med 2013;11:350–4.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiYW5uYWxzZm0iO3M6NToicmVzaWQiO3M6ODoiMTEvNC8zNTAiO3M6NDoiYXRvbSI7czoyMDoiL2phYmZwLzI4LzQvNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

57. 57.American College of Obstetricians and Gynecologists. Exposure to toxic environmental agents. Washington DC: ACOG; 2013.
    
    

58. 58.Mickelson KD. Seeking social support: parents in electronic support groups. Culture of the Internet. Mahwah, NJ: Erlbaum;1997:157–78.
    
    

59. 59.Losh SC. Generation, education, gender and ethnicity in American digital divides. In: Handbook of research on overcoming digital divides: constructing an equitable and competitive information society. Vol. 1. Hershey, PA: IGI Global;2009:196–222.
    
    

60. 60.Mickelson KD, Wroble M, Helgeson VS. “Why my child?”: parental attributions for children's special needs1. J Applied Soc Psychol 1999;29:1263–91.
    
    

61. 61.Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies: III. Design options. Am J Epidemiol 1992;135:1042–50.
    
    [Abstract/FREE Full Text](http://www.jabfm.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYW1qZXBpZCI7czo1OiJyZXNpZCI7czoxMDoiMTM1LzkvMTA0MiI7czo0OiJhdG9tIjtzOjIwOiIvamFiZnAvMjgvNC80NjEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

62. 62.Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health. 1995;50:119–29.
    
    [CrossRef](http://www.jabfm.org/lookup/external-ref?access_num=10.1080/00039896.1995.9940889&link_type=DOI) 
    
    [PubMed](http://www.jabfm.org/lookup/external-ref?access_num=7786048&link_type=MED&atom=%2Fjabfp%2F28%2F4%2F461.atom) 
    
    [Web of Science](http://www.jabfm.org/lookup/external-ref?access_num=A1995RE75500006&link_type=ISI)